Medicus Pharma’s Teverelix shows positive efficacy and safety in premenopausal women
Esme Needham | January 13, 2026 | News story | Research and Development | Endocrinology, Medicus Pharma, Teverelix
Medicus Pharma’s Teverelix has demonstrated long-lasting hormone suppression, as well as a favourable safety profile, in new study data.
Teverelix is a long-acting gonadotropin-releasing hormone (GnRH) antagonist whose possible indications include endometriosis. Two phase 1 clinical studies of Teverelix evaluated its effect on 48 healthy premenopausal women, divided into 30mg, 45mg and 60mg treatment groups as well as a placebo group.
The studies found that Teverelix achieved rapid suppression of both luteinising hormone (LH) and follicle-stimulating hormone (FSH) within 24 hours of administration. It also demonstrated dose-dependent and reversible suppression of oestradiol and long-lasting efficacy. Following a single high-dose injection, participants were found to have hormone suppression that lasted up to two or three weeks.
Teverelix also demonstrated a favourable safety profile. The researchers observed stable bone turnover markers in the study and found no evidence of short-term bone loss from treatment.
The study data will be presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 in Las Vegas, Nevada.
“We believe that these findings reinforce the versatility of Teverelix as a long-acting GnRH antagonist platform,” stated Dr Raza Bokhari, executive chairman and CEO of Medicus. “In addition to its development in prostate cancer and acute urinary retention relapse prevention, we believe these phase 1 results support advancement into a women’s health indication, endometriosis, a condition affecting ~10% of women of reproductive age worldwide, where controlled, reversible hormone suppression and bone safety are critical.
“We are currently engaged in regulatory planning for a phase 2, genomics-informed study of Teverelix in women with symptomatic endometriosis in the United Arab Emirates.”
Medicus is a biotechnology and life sciences company.
Related Content
Medicus Pharma shares updates on basal cell carcinoma trials
Medicus Pharma has announced updates on the progress of SKNJCT-003 and SKNJCT-004, its clinical trials …
